Mixing sumatriptan: a prospective study of stratified care using multiple formulations.

Area of Science:

• Neurology
• Pharmacology

Background:

• Stratified care aligns treatment with disease severity.
• Multiple sumatriptan formulations offer a logical approach to stratified migraine care.
• Limited data exists on using multiple sumatriptan formulations within a single patient group.

Purpose of the Study:

• To evaluate the acceptability, utility, and tolerability of a stratified care system for acute migraine.
• To assess the use of multiple sumatriptan formulations in a single patient population.

Main Methods:

• Prospective, open-label, outpatient study.
• Patients with International Headache Society diagnostic codes 1.1 or 1.2 and prior sumatriptan response were enrolled.
• Subcutaneous sumatriptan was permitted as primary or rescue therapy.

Main Results:

• High enrollment rates for both tablet (80%) and nasal spray (85%) users.
• Significant use of subcutaneous sumatriptan (61% of tablet users, 85% of nasal spray users) within 6 months.
• The system was effective and well-tolerated, with 92% patient satisfaction, though 2% cited lack of efficacy and 6% adverse events.

Conclusions:

• Stratified care utilizing multiple sumatriptan formulations is an effective and well-tolerated migraine management strategy.
• This multi-formulation approach is preferred over single-formulation sumatriptan programs.
• Subcutaneous sumatriptan serves as a valuable rescue treatment in a stratified care model.